跳到正文
原文
Medical Xpress·· 2026-10-15AI 评分45

细胞类型如何影响 mTOR 蛋白活性在结直肠癌中的作用

How cell type influences the impact of cancer-related protein activity in colorectal cancer

AI 导读

一项发表于 npj Precision Oncology 的研究发现,mTOR 信号在结直肠癌中的作用取决于其活跃的细胞类型:免疫细胞中的 mTOR 活性与更强的免疫反应及更好的患者生存相关。

正文
Cell type influences the impact of cancer-related protein activity in colorectal cancer
A schematic overview of the study, where many of the indicated analyses can be performed concurrently. Credit: npj Precision Oncology (2026). DOI: 10.1038/s41698-026-01674-w

Research has revealed that the role of an important protein in colorectal cancer may vary significantly depending on which cells it is active in. The study, published in the journal npj Precision Oncology, shows that activity of a protein called mTOR may be associated with a stronger immune response in colorectal cancer when it is active in immune cells.

Mechanistic target of rapamycin, or mTOR, is a protein that plays an important role in cell signaling—a system of molecular messages that allows cells to regulate various biological functions. mTOR helps cells respond to nutrients and environmental conditions and influences growth, proliferation and immune activity. Because cancer cells often depend on these processes to grow and divide, mTOR signaling is a common feature in many cancers.

"Our findings show that mTOR signaling can have very different effects depending on which cells it is active in. In colorectal cancer, we found that activity in immune cells was associated with a stronger immune response and better patient survival, highlighting the importance of understanding signaling within the wider tumor environment," said Dr. Heba Sailem, reader in computational pathology, King's College London.

Tracing mTOR activity across cell types

One way researchers can tell that mTOR signaling is active is by checking to see whether proteins downstream of it have a phosphate group added—a process called phosphorylation. The researchers in this study were particularly interested in phosphorylated 4EBP1, a marker associated with mTOR activity.

Previous studies looking at p4EBP1 levels across the whole tumor have produced conflicting results about whether mTOR activity suppresses or supports the growth of cancer. This paper, however, investigated whether the biological effect may depend heavily on whether p4EBP1 is present in cancer cells, stromal cells or immune cells.

By looking at these different cell types simultaneously, the researchers were able to investigate mTOR activity not only in the cancer cells themselves, but across the wider tumor microenvironment.

The researchers analyzed tissue from 746 colorectal tumors using highly multiplexed imaging capable of measuring 61 different protein markers at the same time. This allowed them to identify individual cancer cells, immune cells and stromal cells, while also measuring signaling of markers such as p4EBP1 and pS6.

Immune-cell activity linked to longer survival

They found that mTOR activity in immune cells was associated with better patient survival. Patients whose tumors contained immune cells positive for p4EBP1 lived roughly nine months longer on average.

The researchers showed that immune cells in the tumor containing p4EBP1 had increased expression of genes associated with immune activation and function. They also found signals suggesting involvement of neutrophils, another type of immune cell.

Blocking mTOR could have mixed effects

The researchers believe the results could have implications for drugs designed to inhibit mTOR signaling in cancer. While mTOR activity can promote cancer-cell growth, the findings suggest that its activity in immune cells may also be associated with antitumor immune responses, meaning that blocking mTOR activity could have mixed effects.

Instead, new drugs may be able to target specific cells in patients, blocking mTOR in cells where it promotes cancer growth while preserving its activity in immune cells. As such, understanding these cell-specific differences could help inform more personalized approaches to treatment.

Publication details

Razan Zuhair et al., Decoding spatial mTOR signalling reveals distinct roles in the tumour microenvironment, npj Precision Oncology (2026). DOI: 10.1038/s41698-026-01674-w

Journal information: npj Precision Oncology

Clinical categories

Oncology

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: How cell type influences the impact of cancer-related protein activity in colorectal cancer (2026, October 15) retrieved 15 October 2026 from https://medicalxpress.com/news/2026-10-cell-impact-cancer-protein-colorectal.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com